NYMXF supply chain intelligence for Nymox Pharmaceutical Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Nymox Pharmaceutical Corporation (NYMXF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RECORDATI-IRELAND-LTD | RECORDATI-IRELAND-LTD | 90% | 4(t)* License and Collaboration Agreement between Nymox Pharmaceutical Corporation and Recordati Ireland Ltd. dated December 16, 2010. |
| MASSACHUSETTS-GENERAL-HOSPITAL-CORPORATION | MASSACHUSETTS-GENERAL-HOSPITAL-CORPORATION | 80% | 4(c) Research and License Agreement between the Massachusetts General Hospital Corporation and the Corporation |
| RHODE-ISLAND-HOSPITAL-CORPORATION | RHODE-ISLAND-HOSPITAL-CORPORATION | 80% | 4(i) Research and License Agreement between the Rhode Island Hospital Corporation and the Corporation dated May 14, 1999 |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JASPAS-INVESTMENTS-LIMITED | JASPAS-INVESTMENTS-LIMITED | 90% | 4(e) Common Stock Purchase Agreement between Nymox Pharmaceutical Corporation and Jaspas Investments Limited dated November 1, 1999 |
| LORROS-GREYSE-INVESTMENTS-LTD | LORROS-GREYSE-INVESTMENTS-LTD | 90% | 4(s) Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2010. |
| CORPORATION-NYMOX-PHARMACEUTICAL-CORPORATION | CORPORATION-NYMOX-PHARMACEUTICAL-CORPORATION | 62% | d Affordable Care Act. Important market reforms have begun and will continue through full implementation in 2016 and beyond. The law is expected to expand access to health care, and these changes may… |
| CT-CORPORATION | CT-CORPORATION | 62% | d Affordable Care Act. Important market reforms have begun and will continue through full implementation in 2016 and beyond. The law is expected to expand access to health care, and these changes may… |
| DMS-PHARMACEUTICAL-INC | DMS-PHARMACEUTICAL-INC | 62% | d Affordable Care Act. Important market reforms have begun and will continue through full implementation in 2016 and beyond. The law is expected to expand access to health care, and these changes may… |
| EXCHANGE-ACT-THE-CORPORATION | EXCHANGE-ACT-THE-CORPORATION | 62% | as outlined in note 23 - Capital disclosures. The Corporation does not have an operating credit facility and has historically financed its activities primarily through an equity financing agreement w… |
| GOING-CONCERN-THE-CORPORATION | GOING-CONCERN-THE-CORPORATION | 62% | l and management resources. For example, an approval for a product may be conditioned on our conducting costly post-marketing follow-up studies. In addition, if based on these studies, a regulatory a… |
| NYMOX-CORPORATION-NYMOX-CORPORATION | NYMOX-CORPORATION-NYMOX-CORPORATION | 62% | d Affordable Care Act. Important market reforms have begun and will continue through full implementation in 2016 and beyond. The law is expected to expand access to health care, and these changes may… |
| STOCK-THE-CORPORATION | STOCK-THE-CORPORATION | 62% | d Affordable Care Act. Important market reforms have begun and will continue through full implementation in 2016 and beyond. The law is expected to expand access to health care, and these changes may… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NYMXF-DEBT | Debt stack $3.3M | 90% | Market cache reports total debt of $3.3M. |